Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Self-citationGlennon, R. A., Dukat, M., El-Bermawy, M., Law, H., De Los Angeles, J., Teitler, M., King, A., & Herrick-Davis, K. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00039a004 · Cited by 67
Differential phospholipase C activation by phenylalkylamine serotonin 5‐HT2Areceptor agonists
Parrish, J. C., Braden, M. R., Gundy, E., & Nichols, D. E. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03477.x · Cited by 41 · cited 9×
“The Hh2A hi cell line established previously (Parrish et al. , 2005) has a [ 3 H]ketanserin B max of ca. 9000 fmol/mg.”
BackgroundMethodInfluentialSelf-citation
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Self-citationGPCRdb: an information system for G protein-coupled receptors
Isberg, V., Mordalski, S., Munk, C., Rataj, K., Harpsøe, K., Hauser, A. S., Vroling, B., Bojarski, A. J., Vriend, G., & Gloriam, D. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1178 · Cited by 1,072
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Self-citationReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
“Although N-alkyl substituted phenylalkylamines are usually inactive as hallucinogens, the addition of a N-benzyl group to phenethylamines can dramatically increase their activity, and N-benzylphenethylamines are a new class of potent hallucinogenic compounds (Braden et al., 2006).”
BackgroundFribourg, M., Moreno, J. L., Holloway, T., Provasi, D., Baki, L., Mahajan, R., Park, G., Adney, S. K., Hatcher, C., Eltit, J. M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.055 · Cited by 311
Clinical toxicology of newer recreational drugs
Hill, S. L., & Thomas, S. H. L. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.615318 · Cited by 290
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
“In addition, the potency of phenylalkylamine hallucinogens has been found to increase markedly if an N -benzyl moiety is added (e.g., 25I-NBOMe) (Braden et al., 2006; Halberstadt and Geyer, 2014) or if the ring-sub-stituents are incorporated into rigid furan rings (e.g., bromo-Dragonfly, which is…”
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Ettrup, A., Hansen, M., Santini, M. A., Paine, J., Gillings, N., Palner, M., Lehel, S., Herth, M. M., Madsen, J., Kristensen, J., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1686-8 · Cited by 128
“For compounds previously tested, EC50 values are in agreement with reported data [10].”
BackgroundResultInfluentialDark Classics in Chemical Neuroscience: Mescaline
Cassels, B. K., & Sáez-Briones, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00215 · Cited by 85
Ettrup, A., Svarer, C., McMahon, B., da Cunha-Bang, S., Lehel, S., Møller, K., Dyssegaard, A., Ganz, M., Beliveau, V., Jørgensen, L. M., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.02.001 · Cited by 72
“Although both altanserin and Cimbi-36 have high affinity for the 5-HT2A receptor, the two compounds have distinct pharmacological properties: Altanserin is an antagonist (Kristiansen et al., 2005) while Cimbi-36 is an agonist at the 5-HT2A receptor (Braden et al., 2006; Ettrup et al., 2011).”
BackgroundElmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.033 · Cited by 58
Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET
Ettrup, A., Palner, M., Gillings, N., Santini, M. A., Hansen, M., Kornum, B. R., Rasmussen, L. K., Någren, K., Madsen, J., Begtrup, M., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.074021 · Cited by 50
Nielsen, L. M., Holm, N. B., Leth‐Petersen, S., Kristensen, J. L., Olsen, L., & Linnet, K. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2031 · Cited by 44
Metabolic Fate of Hallucinogenic NBOMes
Leth-Petersen, S., Gabel-Jensen, C., Gillings, N., Lehel, S., Hansen, H. D., Knudsen, G. M., & Kristensen, J. L. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00450 · Cited by 43
Kelley, D. P., Venable, K., Destouni, A., Billac, G., Ebenezer, P., Stadler, K., Nichols, C., Barker, S., & Francis, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00660 · Cited by 42
Pottie, E., Kupriyanova, O. V., Brandt, A. L., Laprairie, R. B., Shevyrin, V. A., & Stove, C. P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00189 · Cited by 24
Metadata
- Authors
- Braden, M. R., Parrish, J. C., Naylor, J. C., & Nichols, D. E.
- Venue
- Molecular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2006-12
- Volume
- 70
- Issue
- 6
- Pages
- 1956-1964
- ISSN
- 0026-895X (ISSN-L)
- OpenAlex
- W1972820606
- Cited by
- 215
- References
- 3
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.